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Purpose: To assess the point prevalence of undetected prediabetes (preDM) and diabetes 
mellitus (DM) in patients treated with antipsychotics and to compare metabolic parameters 
between patients with normoglycemia (NG), preDM, and DM. Furthermore, conversion rates 
for preDM and DM were determined in a 1-year follow-up.
Patients and methods: In a naturalistic cohort of 169 patients, fasting glucose (FG) 
and hemoglobin A
1c
 (HbA
1c
) criteria were applied at baseline and at follow-up after 1 year. 
A distinction was made between baseline patients diagnosed according to FG (B-FG) and 
those diagnosed according to HbA
1c
 (B-HbA
1c
). Conversion rates in the 1-year follow-up were 
compared between B-FG and B-HbA
1c
.
Results: At baseline, preDM and DM were present in 39% and 8%, respectively. As compared 
to patients with NG, metabolic syndrome was significantly more prevalent in patients with 
preDM (62% vs 31%). Although the majority of patients were identified by the FG criterion, 
HbA
1c
 contributed significantly, especially to the number of patients diagnosed with preDM 
(32%). Regarding the patients with preDM, conversion rates to NG were much higher in the 
B-FG group than in the B-HbA
1c
 group (72% vs 18%). In patients diagnosed with DM, conver-
sion rates were found for B-FG only.
Conclusion: PreDM and DM are highly prevalent in psychiatric patients treated with 
antipsychotic drugs. HbA
1c
 was shown to be a more stable parameter in identifying psychiatric 
patients with (an increased risk for) DM, and it should therefore be included in future screen-
ing instruments.
Keywords: severe mental illness, prediabetes, diabetes, fasting glucose, HbA
1c
Introduction
Diabetes mellitus (DM) is a chronic illness that has been associated with a two- to 
three-fold increased incidence of cardiovascular disease independent of other well-
known risk factors.1,2 For decades, either the fasting glucose (FG) or the 2-hour value 
in the oral glucose tolerance test was used as a major criterion for the diagnosis of 
DM. Since glycosylated hemoglobin A
1c
 (HbA
1c
) is a reliable measure of long-term 
glycemic exposure and is strongly correlated with diabetic complications, the American 
Diabetes Association (ADA) included HbA
1c
, for which no fasting conditions are neces-
sary, as an additional diagnostic test.3,4 Hyperglycemia that does not fulfill diagnostic 
criteria for DM is known as prediabetes (preDM). PreDM is commonly associated 
with (components of) metabolic syndrome (MetS),5,6 and is a strong risk factor for 
the future development of DM and cardiovascular events.7,8 Detection of preDM is of 
special importance to prevent or delay the development of DM by means of lifestyle 
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interventions such as dietary change and regular physical 
exercise.9,10 In an effort to identify persons with preDM, 
diagnostic categories of impaired fasting glucose, impaired 
glucose tolerance, and HbA
1c
 have been established.4
Patients with severe mental illness (SMI) have a disease-
related increased risk of both hyperglycemia and DM,11–13 
which can further be raised by treatment with antipsychotics, 
known to induce or worsen glycemic dysregulation.14–16 There 
seems to be, however, a lack of monitoring and management 
of glycemic abnormalities in patients with SMI.17  Therefore, 
the treating clinician should be aware of the potential car-
diometabolic risk, and a multidisciplinary assessment of 
psychiatric and somatic health care is warranted.18
In a recent study, preDM was found to be present in 
37% of patients treated with antipsychotics and appeared to 
be correlated with markers of central obesity, dyslipidemia, 
and insulin resistance.19 Furthermore, it was shown that the 
simultaneous use of the FG and HbA
1c
 criteria identifies the 
majority of patients with preDM.
The primary aim of the present study was to assess the 
point prevalence of undetected preDM and DM in patients 
treated with antipsychotics using the FG and HbA
1c
 criteria, 
and to compare metabolic parameters between patients with 
normoglycemia (NG), preDM, and DM. In addition, conver-
sion rates from NG to preDM and DM and vice versa were 
calculated in a 1-year follow-up to determine the number of 
patients developing or reversing glycemic abnormalities. To 
assess stability over time of the diagnostic parameters FG and 
HbA
1c
, baseline values of FG (B-FG) and HbA
1c
 (B-HbA
1c
) 
were compared with those after 1-year follow-up.
Material and methods
Study design and subjects
This naturalistic cohort study was conducted at the outpatient 
departments of the Vincent van Gogh Institute for Psychiatry 
in the Netherlands and approved by the Institutional Review 
Board of the psychiatric training hospital. Informed consent 
was obtained from all patients. A health monitor was intro-
duced as a screening instrument in a treatment and recovery 
program at the outpatient departments. From November 
2008 to July 2011, 169 patients had complete assessments 
at baseline and after 1-year follow-up.
Assessment of parameters
Trained nurse practitioners conducted a standardized patient 
interview and studied medical records to collect information 
about DSM-IV (Diagnostic and Statistical Manual of Men-
tal Disorders, Fourth Edition) diagnoses, smoking status, 
substance abuse, prescription of psychiatric and somatic 
medications, (family) history of cardiovascular disease, 
and/or DM. Furthermore, a physical examination was per-
formed, including measurements of height (cm), body weight 
(kg), waist circumference (cm), and arterial blood pressure 
(mmHg). Laboratory tests comprised FG, HbA
1c
, triglycer-
ides (TG), total cholesterol, high density lipoprotein (HDL) 
cholesterol, and low density lipoprotein cholesterol.
All patients and/or their caregivers were clearly instructed 
that blood sampling had to be performed under fasting 
conditions.
Evaluation of somatic parameters
Patients were categorized according to the FG and HbA
1c
 
criteria from the ADA as having NG (FG ,5.6 mmol/L 
or HbA
1c
 ,5.7%), preDM (FG 5.6–6.9 mmol/L or HbA
1c
 
5.7%–6.4%), or DM (FG $7.0 mmol/L or HbA
1c
 $6.5%).4 
Body mass index (BMI) was calculated (kg/m2), and obesity 
was present when BMI $30 kg/m2.
According to the European guidelines on cardiovascular 
disease prevention in clinical practice,20 a diagnosis of hyper-
tension was based on a systolic blood pressure $140 mmHg 
and/or diastolic blood pressure $90 mmHg, or use 
of antihypertensive medication. In addition, high TG 
($1.7 mmol/L), low HDL cholesterol (female ,1.3 mmol/L, 
male ,1.0 mmol/L), and high low-density lipoprotein 
cholesterol ($3.0 mmol/L or treatment with lipid-lowering 
agents) were defined.
MetS was defined according to the National Cholesterol 
Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel-III) (ATP-III) guidelines,21 
and the diagnosis was made when patients fulfilled three 
or more of the following five criteria: waist circumference 
.88 cm in women and .102 cm in men, fasting blood glu-
cose $6.1 mmol/L or treatment with antidiabetic medication, 
HDL ,1.3 mmol/L in women and ,1.0 mmol/L in men, 
TG $1.7 mmol/L, and blood  pressure $130/85 mmHg or 
treatment with antihypertensives.
Statistical analyses
The percentages of patients who fulfilled criteria for NG, 
preDM, and DM according to FG or HbA
1c
 criteria were 
calculated at baseline and follow-up. Independent sample 
t-tests and chi-square tests were used to compare demo-
graphic, clinical, and cardiometabolic parameters between 
patients with NG, preDM, and DM. The percentages of 
patients developing or reversing preDM or DM were 
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calculated. All data were analyzed using SPSS 16.0 for 
Windows. Statistical significance was considered at the 
level of P,0.05.
Results
Demographic and clinical characteristics
In a period of 32 months, 169 patients with SMI, previ-
ously known to be nondiabetic, were examined at baseline 
and after 1-year follow-up. Demographic and clinical 
characteristics of this group are presented in Table 1. 
 Concerning antipsychotic treatment at baseline, the major-
ity of patients used  antipsychotic monotherapy (n=148; 
88%).  Conventional antipsychotics were prescribed to 
41 patients (28%)  (haloperidol: n=18;  zuclopenthixole: 
n=11; pimozide: n=3; flupenthixol: n=4;  bromperidol: n=2; 
penfluridol: n=2; fluspirilene: n=1). A total of 107 patients 
(72%) received atypical antipsychotics  (risperidon: n=42; 
olanzapine: n=17;  quetiapine: n=10; aripiprazole: n=5; 
clozapine: n=32;  sertindole: n=1).  Twenty-one patients 
(12%) were treated with two antipsychotics  (conventional 
only: n=3; atypical only: n=7; conventional and atypical: 
n=11). At follow-up after 1 year, there were no significant 
changes in antipsychotic treatment regiments or cardio-
metabolic parameters.
Prevalence of NG, preDM, and DM  
at baseline and follow-up
At baseline, 90 out of 169 patients (53%) were identified 
with NG, whereas 66 (39%) fulfilled criteria for preDM 
(FG only: n=32, HbA
1c
 only: n=21, both: n=13) (Figure 
1), and 13 (8%) were diagnosed with DM (FG only: n=11, 
HbA
1c
 only: n=1, both: n=1). As compared to patients with 
NG, prediabetic patients had a larger waist circumfer-
ence (106 cm vs 99 cm, P,0.001), higher BMI (30 kg/
m2 vs 27 kg/m2, P,0.001), higher systolic blood pressure 
(128 mmHg vs 123 mmHg, P=0.011), higher diastolic 
blood pressure (86 mmHg vs 81 mmHg, P,0.001), and 
higher TG levels (2.4 mmol/L vs 1.8 mmol/L, P,0.001) 
(Table 2). As shown in Figure 2, patients with preDM were 
more frequently diagnosed with obesity (41% vs 20%, 
P=0.004), high TG (62% vs 43%, P=0.02), low HDL (58% 
vs 34%, P=0.004), and MetS (62% vs 31%, P,0.001). 
No significant differences in age, sex, family history of 
cardiovascular disease or DM, psychiatric diagnoses, 
smoking status, number or type of antipsychotic agent(s), 
Table 1 Demographic and clinical characteristics of the study 
group at baseline and follow-up after 1 year
N=169 N=169
Mean age ± SD 41±12 42±12
Male/female 102/67 (60%/40%) 102/67 (60%/40%)
Caucasian 125 (74%) 125 (74%)
Smoking 91 (54%) 88 (52%)
DSM-IV classification
 Schizophrenia 96 (57%) 96 (57%)
 Schizoaffective disorder 26 (15%) 29 (17%)
 Other psychotic disorder 42 (25%) 38 (23%)
 Bipolar disorder 2 (1%) 2 (1%)
 Others 3 (2%) 4 (2%)
Mean duration of illness  
(years ± SD)
13±8 14±8
Number of antipsychotic agents
 One antipsychotic 148 (88%) 135 (80%)
 $2 Antipsychotics 21 (12%) 28 (17%)
Other psychotropics
 Antidepressants 38 (23%) 34 (20%)
 Mood stabilizers 28 (17%) 26 (15%)
 Benzodiazepines 63 (37%) 64 (38%)
Cardiometabolic parameters
 BMI (kg/m2) 27.9 28.1
 Waist circumference (cm) 102.1 102.0
 Blood pressure (mmHg) 127/83 124/82
 Total cholesterol (mmol/L) 5.4 5.2
 LDL (mmol/L) 3.3 3.2
 HDL (mmol/L) 1.2 1.2
 TG 2.1 2.1
 FG (mmol/L) 5.5 5.4
 HbA1c (%) 5.4 5.5
Abbreviations: BMI, body mass index; DSM-IV, Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition; FG, fasting glucose; HbA1c, glycosylated hemoglobin; 
HDL, high density lipoprotein; LDL, low density lipoprotein; TG, triglycerides.
FG 5.6–6.9 mmol/L
HbA1c 5.7%–6.4%
N=32
N=13
N=21
Figure 1 Number of baseline patients with preDM (n=66) according to FG only 
(n=32), HbA1c only (n=21), or both (n=13).
Abbreviations: FG, fasting glucose; HbA1c, glycosylated hemoglobin; preDM, 
prediabetes.
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n=2). The remaining 106 patients (63%) did not fulfill the 
criteria for hyperglycemia and were  classified as NG.
Follow-up data of patients  
with NG at baseline (n=90)
Of the 90 normoglycemic patients at baseline, after 1 year, 74 
patients (82%) were still normoglycemic. In 13 patients (15%), 
conversion to preDM was found (FG only: n=11, FG and HbA
1c
: 
n=2), whereas three (3%) had developed DM (FG only: n=3).
Follow-up data of patients  
with preDM at baseline (n=66)
At baseline, 32 patients were diagnosed with preDM according 
to the FG criterion only (B-FG). As depicted in Figure 3A, after 1 
year, 23 patients (72%) reversed to NG, eight patients (25%) still 
fulfilled criteria for preDM (FG only: n=6, FG and HbA
1c
 only: 
n=2), and only one patient (3%) developed DM (FG only).
Of the 34 B-HbA
1c
 patients with preDM, six patients 
(18%) reversed to NG, 24 (70%) were still diagnosed with 
preDM (FG only: n=5, HbA
1c
 only: n=13, both: n=6), and 
four (12%) fulfilled criteria for DM (FG only: n=3, HbA
1c
 
only: n=1) (Figure 3B).
Thus, after 1 year, 28% (25% + 3%) of the B-FG patients 
vs 82% (70% + 12%) of the B-HbA
1c
 patients remained in 
a hyperglycemic state.
Table 2 Cardiometabolic parameters in patients with NG, 
preDM, and DM
NG  
(n=90)
PreDM  
(n=66)
DM  
(n=13)
Waist circumference (cm) 99 106* 105
BMI (kg/m2) 27 30* 29
Systolic blood pressure (mmHg) 123 128* 136
Diastolic blood pressure (mmHg) 81 86* 87
Total cholesterol (mmol/L) 5.3 5.4 1.4
HDL (mmol/L) 1.3 1.1 1.1
LDL (mmol/L) 3.3 3.3 3.3
TG (mmol/L) 1.8 2.4* 3.0
Note: *Significant difference between preDM and NG (P,0.05).
Abbreviations: BMI, body mass index; DM, diabetes mellitus; HDL, high density 
lipoprotein; LDL, low density lipoprotein; NG, normoglycemia; preDM, prediabetes; 
TG, triglycerides.
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Figure 2 Frequencies of cardiometabolic parameters in patients with NG (n=90), preDM (n=66), and DM (n=13).
Note: *Significant differences (P,0.05) between patients classified as preDM vs NG.
Abbreviations: DM, diabetes mellitus; HDL, high density lipoprotein; LDL, low density lipoprotein; MetS, metabolic syndrome; NG, normoglycemia; preDM, prediabetes; 
TG, triglycerides.
or co-medication with antidepressants and/or mood stabi-
lizers were found.
In comparison to diabetic patients, patients with preDM 
were younger (42 years vs 50 years, P=0.001). There were no 
significant differences in sex, family history of cardiovascular 
disease or DM, cardiometabolic parameters, smoking status, 
psychiatric diagnoses, and psychotropic treatment variables 
between prediabetic and diabetic patients.
After 1 year, 49 out of 169 patients (29%) were diagnosed 
with preDM (FG only: n=25, HbA
1c
 only: n=16, both: n=8) 
and 14 (8%) with DM (FG only: n=11, HbA
1c
 only: n=1, both: 
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Follow-up data of patients  
with DM at baseline (n=13)
After 1 year, three of the eleven B-FG patients (28%) 
reversed to NG, four patients (36%) fulfilled criteria for 
preDM (FG only: n=3, HbA
1c
 only: n=1), and four patients 
(36%) still fulf illed criteria for DM (FG only: n=4). 
The two B-HbA
1c
 patients still fulfilled criteria for DM at 
follow-up.
Discussion
The present study demonstrates that, using FG and HbA
1c
 
criteria, undetected preDM and DM were present in 39% 
and 8% of SMI patients treated with antipsychotics, 
respectively. Although in the present study the majority of 
prediabetic and diabetic patients were diagnosed by the FG 
criterion, HbA
1c
 appeared to contribute significantly to the 
number of patients identified, especially those with preDM 
(32%). As compared to patients with NG, cardiometabolic 
parameters, including MetS, were more prevalent in patients 
with preDM. These findings are in line with data reported 
elsewhere.19
After 1 year, the prevalence of preDM had decreased 
about 10% but that of DM did not change. A more detailed 
analysis of the conversion rates, however, disclosed that over 
a period of 1 year, 15% vs 3% of the baseline normoglyce-
mic patients developed preDM and DM, respectively. Of 
the patients with preDM at baseline, in 7% (five out of 66) 
DM was diagnosed at follow-up. The incidence rate of DM 
in these SMI patients is about ten-fold as high as compared 
to the general population in the Netherlands (0.2%–0.3%).22 
PreDM  
(B-HbA1c) 
n=34 
(100%) 
NG
n=6
(18%)
PreDM
n=24
(70%)
DM
n=4
(12%) 
PreDM
(B-FG)
n=32
(100%)
NG
n=23
(72%)
PreDM
n=8
(25%)
DM
n=1
(3%)
A
B
Figure 3 Follow-up on patients with a baseline diagnosis of preDM according to (A) FG criteria only (B-FG) (n=32) and (B) HbA1c criteria (B-HbA1c) (n=34).
Abbreviations: B-FG, baseline patients diagnosed according to FG; DM, diabetes mellitus; FG, fasting glucose; HbA1c, glycosylated hemoglobin; NG, normoglycemia; 
B-HbA1c, baseline patients diagnosed according to HbA1c; preDM, prediabetes.
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These findings stress the high cardiometabolic risk of patients 
with SMI. On the other hand, it cannot be ruled out a fortiori 
that during this 1-year period, changes in lifestyle have con-
tributed to a change in glucose state.
It should be underlined, however, that a substantial number 
of patients with a baseline diagnosis of preDM or DM showed 
conversion to NG at follow-up, ie, 44% or 23%, respectively. 
This phenomenon may be explained by the dynamic course of 
glucose metabolism, which stresses the need for systematic and 
repeated evaluation of glucose parameters.23 The reversion into 
a normoglycemic state also raises the question about the use 
of FG as a diagnostic test. In this study, it was shown that the 
conversion rates were higher in patients with hyperglycemia 
according to FG in comparison to HbA
1c
. After 1 year, 82% 
of the B-HbA
1c
 patients remained in a hyperglycemic state as 
compared to only 28% of the B-FG patients. Therefore, HbA
1c
 
seems to be a more stable parameter over time in diagnosing 
glucose abnormalities in patients with SMI. Nevertheless, in 
contrast to the ADA, the World Health Organization states 
that there is currently insufficient evidence to make a formal 
recommendation on the interpretation of HbA
1c
 levels below 
6.5%.24 Furthermore, it is worth mentioning that, since HbA
1c
 
reflects the average glucose levels over the past 6–8 weeks, 
acute changes in glucose metabolism potentially induced by 
antipsychotics cannot be detected.
It is worth noting that a diagnosis of preDM or diabetes 
was established according to only one laboratory  assessment. 
When glycemic abnormalities were found, patients were sent 
to their general practitioner for further analysis, lifestyle 
advice, and somatic treatment when indicated. Unfortunately, 
information about the number of patients in whom lifestyle 
modification took place was not collected and therefore its 
possible contribution to change in glucose metabolism could 
not be assessed. Another limitation is the relatively small 
sample size, so the results may not be representative of all 
antipsychotic-treated patients. Long-term follow-up studies 
of glucose metabolism in larger sample sizes are warranted to 
better understand glucose metabolism in patients with SMI.
In conclusion, systematic evaluation of glucose parameters 
in antipsychotic-treated patients is necessary, in order to detect 
glucose dysregulations at an early stage and to prevent prema-
ture metabolic and cardiovascular complications. As there is no 
need for a fasting condition and HbA
1c
 is more stable over time, 
this test should be used, in addition to FG, to screen for glucose 
abnormalities in psychiatric patients at risk for DM. Further 
studies are warranted to assess the course of glucose dysregu-
lation in patients with SMI in order to establish an appropriate 
screening instrument and somatic treatment protocol.
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